Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With HER2 Negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Oesogastric Junction Adenocarcinoma
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Oxaliplatin (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms LOGICAN
Most Recent Events
- 01 Aug 2024 Trial designed of this study published in the Digestive and Liver Disease.
- 12 Apr 2023 Planned initiation date (estimated date of first participant enrollment) changed from 14 Mar 2023 to 14 Dec 2023.
- 10 Feb 2023 Planned End Date changed from 1 Oct 2027 to 1 Jan 2027.